Respiratory syncytial virus (RSV) IgM antibody detection kit (enzyme-linked immunosorbent assay)

Respiratory syncytial virus (RSV) IgM antibody detection kit (enzyme-linked immunosorbent assay)

Respiratory syncytial virus (RSV) IgG antibody detection kit (enzyme-linked immunosorbent assay)

Respiratory syncytial virus (RSV) belongs to the family of pneumonia viruses and is a enveloped, non segmented, negative sense RNA virus. Mainly causing lower respiratory tract infections such as bronchiolitis and pneumonia in infants under 6 months old, as well as upper respiratory tract infections such as rhinitis and colds in older children and adults.

Respiratory syncytial virus infection is the primary factor causing hospitalization for viral respiratory infections in infants and young children, seriously endangering children's health, especially for premature infants, infants with congenital heart disease or primary immunodeficiency.  [6]

On September 24, 2024, long-acting monoclonal antibodies, a preventive measure against respiratory syncytial virus (RSV), were administered to all infants at the Ronghua Community Health Service Center in Beijing Economic Development Zone and the Sunhe Community Health Service Center in Chaoyang District.  [11]

Respiratory syncytial virus (RSV) IgM antibody detection kit (enzyme-linked immunosorbent assay)

Respiratory syncytial virus (RSV) IgG antibody detection kit (enzyme-linked immunosorbent assay)

Respiratory syncytial virus (RSV) belongs to the family of pneumonia viruses and is a enveloped, non segmented, negative sense RNA virus. Mainly causing lower respiratory tract infections such as bronchiolitis and pneumonia in infants under 6 months old, as well as upper respiratory tract infections such as rhinitis and colds in older children and adults.

Respiratory syncytial virus infection is the primary factor causing hospitalization for viral respiratory infections in infants and young children, seriously endangering children's health, especially for premature infants, infants with congenital heart disease or primary immunodeficiency.  [6]

On September 24, 2024, long-acting monoclonal antibodies, a preventive measure against respiratory syncytial virus (RSV), were administered to all infants at the Ronghua Community Health Service Center in Beijing Economic Development Zone and the Sunhe Community Health Service Center in Chaoyang District.  [11]